Changing boundaries in the treatment of malignant gliomas

Alba A. Brandes, Umberto Basso, Lara M. Pasetto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.

Original languageEnglish
Pages (from-to)357-370
Number of pages14
JournalExpert Review of Anticancer Therapy
Volume1
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Glioma
Combination Drug Therapy
Brain Neoplasms
Survivors
Radiotherapy
Therapeutics
Survival
Research
Pharmaceutical Preparations
Neoplasms

Keywords

  • Angiogenesis
  • Chemotherapy
  • Gene therapy
  • Glioma
  • High grade
  • Nitrosoureas
  • Radiotherapy
  • Temozolomide

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Changing boundaries in the treatment of malignant gliomas. / Brandes, Alba A.; Basso, Umberto; Pasetto, Lara M.

In: Expert Review of Anticancer Therapy, Vol. 1, No. 3, 2001, p. 357-370.

Research output: Contribution to journalArticle

Brandes, Alba A. ; Basso, Umberto ; Pasetto, Lara M. / Changing boundaries in the treatment of malignant gliomas. In: Expert Review of Anticancer Therapy. 2001 ; Vol. 1, No. 3. pp. 357-370.
@article{c171b786044d4ec981514bfe85074792,
title = "Changing boundaries in the treatment of malignant gliomas",
abstract = "Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10{\%}. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.",
keywords = "Angiogenesis, Chemotherapy, Gene therapy, Glioma, High grade, Nitrosoureas, Radiotherapy, Temozolomide",
author = "Brandes, {Alba A.} and Umberto Basso and Pasetto, {Lara M.}",
year = "2001",
doi = "10.1586/14787210.1.3.357",
language = "English",
volume = "1",
pages = "357--370",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Changing boundaries in the treatment of malignant gliomas

AU - Brandes, Alba A.

AU - Basso, Umberto

AU - Pasetto, Lara M.

PY - 2001

Y1 - 2001

N2 - Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.

AB - Malignant gliomas are still among the most lethal and difficult tumors to treat; even the most intensive combinations of radio- and chemotherapy are not curative and yield only a modest impact on survival for most of these patients, as long-term survivors are less than 10%. There is a major need for new chemotherapeutic drugs and alternative therapeutic modalities. This review aims to define the best standard treatment in the common clinical practice and also summarizes the most promising lines of investigational research in the field of neuro-oncology, which will probably offer new and long-awaited valid therapy options for brain tumor patients.

KW - Angiogenesis

KW - Chemotherapy

KW - Gene therapy

KW - Glioma

KW - High grade

KW - Nitrosoureas

KW - Radiotherapy

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=0035557911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035557911&partnerID=8YFLogxK

U2 - 10.1586/14787210.1.3.357

DO - 10.1586/14787210.1.3.357

M3 - Article

C2 - 12113103

AN - SCOPUS:0035557911

VL - 1

SP - 357

EP - 370

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 3

ER -